Ruby Wang

No, China Won’t Replace USAID. But Here Are Five New Ways It's Rewriting the Global Health Playbook. As USAID/Western donors retreat, it's feared that China will fill the gaps and disrupt the global health order. In practice, China offers fresh, alternative tools. The Global South is very interested.

open.substack.com/pub/chinahea...

Excited to share my latest post: I break down 5 ways #China is reshaping #globalhealth for the #globalsouth, but not as a #USAID replacement - remote-first #innovation, sovereign #data; public/private integration; community care, traditional blending. Link in comments #healthpolicy #development

Thanks so much @robertpostings.bsky.social !

How Will Trump-China Tariffs Impact Patients, Pharma and Global Health? Headlines are screaming. Stocks are tanking. A global recession may be looming. These US-China tariffs shatter a decades-old principle: that medicines are kept out of trade wars.

open.substack.com/pub/chinahea...

On 9 April, Trump confirmed incoming Pharma tariffs. This shatters a decades long WTO precedent; that medicines are kept out of trade wars. The consequences: innovation slows. supply chains strain, foreign pharma loses & China hardens. My latest post on the #USChina #tariffs:

Health and the Two Sessions (Pt 2 of 2): After Xi’s Recent Global CEO Summit, Who's Responsible for China's Health Agenda? China’s 2025 health future is asking a lot of everyone. Foreign firms are welcomed, and the ageing population is recast as a "silver economy" opportunity—but these are big promises with thin margins.

Link here: open.substack.com/pub/chinahea...

Pt 2 of my special deep dive on #China’s #TwoSessions is out now—the only health-focused analysis of this key political event, incl “silver economy”#health #biotech #ageing #healthpolicy I also analyse context of Xi’s recent global CEO meeting — 25 % of the room was big Pharma!

China’s biotech is getting global attention. In my latest post at <China Health Pulse>, I unpack 4 key truths behind the headlines. Link in comments:
#biotech #china #healthtech #healthpolicy #innovation

Big pharma faces headwinds in China as vaccine sales decline - Pharmaceutical Technology Multinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.

Was interviewed by <Pharmaceutical Technology> on vaccine market access challenges for foreign pharma in China. These include domestic competition, vaccine hesitancy, regulatory hurdles, disease-specific stigma etc. #vaccines #pharma #china #health www.pharmaceutical-technology.com/features/big...

Biotech in China: Four Important Truths That Everyone Isn’t Talking About Is it really the DeepSeek moment everyone keeps saying it is?

open.substack.com/pub/chinahea...

China’s biotech is getting global attention. In my latest post at <China Health Pulse>, I unpack 4 key truths behind the headlines. Link in comments:
#biotech #china #healthtech #healthpolicy #innovation

Thanks Michael!

Five Biggest Myths I See About China’s Healthcare Here’s what everyone keeps getting wrong - and why it really matters.

Most takes on China’s health are wrong. I debunk 5 of the biggest myths - from inequalities to innovation - because bad assumptions lead to real world consequences. Read my newsletter here: #China #health #healthpolicy #globalhealth #innovation #biotech open.substack.com/pub/chinahea...

🚨I launched a newsletter!

“China Health Pulse” decodes how China is reshaping health policy, tech, life sciences markets and the future of global health.

Clear analysis, real insights—no noise. #China #Health #Biotech #HealthPolicy #Substack

Subscribe: open.substack.com/pub/chinahea...